User contributions
Jump to navigation
Jump to search
- 13:05, 4 May 2024 diff hist +151 m Rhabdomyosarcoma →All lines of therapy current
- 13:03, 4 May 2024 diff hist +291 m Rhabdomyosarcoma →VA {{#subobject:a9710b|Regimen=1}}
- 01:10, 4 May 2024 diff hist +74 m Hereditary hemorrhagic telangiectasia - null regimens current
- 01:09, 4 May 2024 diff hist -18 m Hereditary hemorrhagic telangiectasia →Tranexamic acid monotherapy {{#subobject:ea894c|Regimen=1}} current
- 01:07, 4 May 2024 diff hist +44 m Hereditary hemorrhagic telangiectasia →References
- 01:06, 4 May 2024 diff hist +268 m Hereditary hemorrhagic telangiectasia →Tranexamic acid monotherapy {{#subobject:ea894c|Regimen=1}}
- 01:01, 4 May 2024 diff hist +148 m Hereditary hemorrhagic telangiectasia →Tamoxifen monotherapy {{#subobject:b1894c|Regimen=1}}
- 00:59, 4 May 2024 diff hist +152 m Hepatoblastoma →Neoadjuvant therap current
- 00:57, 4 May 2024 diff hist +2,484 m Hepatoblastoma →Adjuvant therapy
- 00:56, 4 May 2024 diff hist -2,461 m Hepatoblastoma →Cisplatin monotherapy {{#subobject:ea894c|Regimen=1}}
- 00:55, 4 May 2024 diff hist +58 m Hepatoblastoma →COG AHEP0731 protocol H - non-responders {{#subobject:3a882f|Regimen=1}}
- 00:54, 4 May 2024 diff hist +4,683 Hepatoblastoma →SIOPEL-4 protocol {{#subobject:3a6ad9|Regimen=1}}
- 00:33, 4 May 2024 diff hist +66 m Follicular lymphoma - historical →ProMACE-MOPP {{#subobject:0aa31b|Regimen=1}} current
- 00:32, 4 May 2024 diff hist +55 m Breast cancer - historical →Methotrexate & Thiotepa {{#subobject:c67a88|Regimen=1}} current
- 23:53, 3 May 2024 diff hist +314 m Classical Hodgkin lymphoma - historical →ABVD {{#subobject:c5a35d|Regimen=1}} current
- 23:49, 3 May 2024 diff hist +70 m Classical Hodgkin lymphoma - historical →NOVP {{#subobject:230457|Regimen=1}}
- 23:44, 3 May 2024 diff hist +478 m Classical Hodgkin lymphoma - historical →COPP/ABVD {{#subobject:92a2c8|Regimen=1}}
- 23:40, 3 May 2024 diff hist +111 m B-cell acute lymphoblastic leukemia, pediatric - historical →L-Asparaginase, Vincristine, Prednisone {{#subobject:87ybf2|Regimen=1}} current
- 23:39, 3 May 2024 diff hist +246 m B-cell acute lymphoblastic leukemia, pediatric - historical →Daunorubicin & Prednisone {{#subobject:aa10e0|Regimen=1}}
- 23:35, 3 May 2024 diff hist +152 m B-cell acute lymphoblastic leukemia, pediatric - historical →Cyclophosphamide monotherapy {{#subobject:cd166d|Regimen=1}}
- 23:33, 3 May 2024 diff hist +392 m B-cell acute lymphoblastic leukemia, pediatric - historical →Daunorubicin, Vincristine, Prednisolone {{#subobject:h1huh5|Regimen=1}}
- 23:29, 3 May 2024 diff hist +256 m B-cell acute lymphoblastic leukemia, pediatric - historical →Daunorubicin, Vincristine, Prednisone {{#subobject:h1huh5|Regimen=1}}
- 20:50, 3 May 2024 diff hist +154 m Extranodal NK- and T-cell lymphoma, nasal type →DEP & RT {{#subobject:d8a9eb|Regimen=1}} current
- 20:46, 3 May 2024 diff hist +355 m Small cell lung cancer - historical →ICE {{#subobject:f535c2|Regimen=1}} current
- 20:43, 3 May 2024 diff hist +451 m Small cell lung cancer - historical →CC/DE & RT {{#subobject:189bcc|Regimen=1}}
- 20:33, 3 May 2024 diff hist -182 m Rhabdomyosarcoma, pediatric current
- 20:28, 3 May 2024 diff hist +1,399 m Classical Hodgkin lymphoma - historical →Untreated
- 20:27, 3 May 2024 diff hist -1,368 m Classical Hodgkin lymphoma →VEBEP {{#subobject:d7a2a6|Regimen=1}} current
- 20:21, 3 May 2024 diff hist +116 m Classical Hodgkin lymphoma →VEBEP {{#subobject:d7a2a6|Regimen=1}}
- 20:04, 3 May 2024 diff hist +3 m Endometrial cancer current
- 19:58, 3 May 2024 diff hist +549 m Classical Hodgkin lymphoma - historical →COPP/ABVD {{#subobject:92a2c8|Regimen=1}}
- 19:20, 3 May 2024 diff hist +137 m Prostate cancer current
- 18:59, 3 May 2024 diff hist +2,641 m Non-small cell lung cancer, squamous →Carboplatin & Paclitaxel (CP) {{#subobject:c5fbdf|Regimen=1}} current
- 18:54, 3 May 2024 diff hist +2,074 Non-small cell lung cancer, squamous →Carboplatin & Paclitaxel (CP) & Pembrolizumab {{#subobject:1dc8a3|Regimen=1}}
- 18:47, 3 May 2024 diff hist +2,076 m Hepatocellular carcinoma current
- 17:07, 3 May 2024 diff hist +55 m Medulloblastoma →Consolidation current
- 17:00, 3 May 2024 diff hist -24 m HIV-associated lymphoma →CNS therapy, prophylaxis {{#subobject:724xbj|Variant=1}} current
- 16:52, 3 May 2024 diff hist +11 m Ewing sarcoma, pediatric current
- 16:51, 3 May 2024 diff hist -80 m Ewing sarcoma, pediatric →COG AEWS1031 Regimen A
- 16:40, 3 May 2024 diff hist -25 m Burkitt lymphoma current
- 12:39, 3 May 2024 diff hist +523 m PJP Prophylaxis current
- 12:34, 3 May 2024 diff hist +33 m Cancer-related fatigue current
- 12:34, 3 May 2024 diff hist +33 m Cancer-related fatigue
- 12:26, 3 May 2024 diff hist +570 m Antidepressants and other psychiatric medications in cancer care current
- 12:22, 3 May 2024 diff hist +93 m Professional organizations current
- 10:57, 3 May 2024 diff hist +1,139 m Head and neck cancer →Cisplatin & RT {{#subobject:c7061f|Regimen=1}} current
- 10:45, 3 May 2024 diff hist +1,725 m Breast cancer, HER2-positive current
- 10:42, 3 May 2024 diff hist +1,080 m Cholangiocarcinoma current
- 01:26, 2 May 2024 diff hist -14 m Immunotherapy toxicity management current
- 01:26, 2 May 2024 diff hist +15 m Immunotherapy toxicity management →Guidelines
- 01:24, 2 May 2024 diff hist -2,558 m Immunotherapy toxicity management →Guidelines
- 01:04, 2 May 2024 diff hist +108 m Category:Guideline pages current
- 01:04, 2 May 2024 diff hist -8 m NCCN guidelines →Fatigue current
- 01:03, 2 May 2024 diff hist -8 m ESMO guidelines →Palliative care current
- 01:03, 2 May 2024 diff hist +36 N Category:Guideline pages Created page with "Category:General reference pages"
- 01:03, 2 May 2024 diff hist -8 m ASCO guidelines current
- 01:02, 2 May 2024 diff hist +32 m NCCN guidelines
- 01:01, 2 May 2024 diff hist -13 m ESMO guidelines
- 01:00, 2 May 2024 diff hist +2 m ASCO guidelines →Pain
- 01:00, 2 May 2024 diff hist +2 m ASCO guidelines
- 01:00, 2 May 2024 diff hist +28 m ASCO guidelines
- 00:05, 2 May 2024 diff hist +634 m Pyruvate kinase deficiency current
- 20:14, 1 May 2024 diff hist +3 m Ovarian cancer →Carboplatin, Pegylated liposomal doxorubicin, Bevacizumab {{#subobject:a38gbb|Regimen=1}} current
- 15:53, 1 May 2024 diff hist +6 m Nasopharyngeal carcinoma current
- 13:47, 1 May 2024 diff hist -167 m Breast cancer →AC-T {{#subobject:633n67|Regimen=1}} current
- 22:56, 30 April 2024 diff hist +209 m How I Treat →Waldenström macroglobulinemia (WM) current
- 22:54, 30 April 2024 diff hist +751 m Follicular lymphoma →References current
- 19:46, 30 April 2024 diff hist +1,008 m Breast cancer, HER2-positive
- 17:35, 30 April 2024 diff hist +1,912 Multiple myeloma, relapsed-refractory →VTD {{#subobject:96881b|Regimen=1}} current
- 17:27, 30 April 2024 diff hist +14 m Multiple myeloma, relapsed-refractory →Regimen variant #2 {{#subobject:fc94h1|Variant=1}}
- 13:11, 30 April 2024 diff hist 0 m Soft tissue sarcoma →Doxorubicin monotherapy {{#subobject:826f82|Regimen=1}} current
- 13:07, 30 April 2024 diff hist +1,701 m Soft tissue sarcoma →Doxorubicin monotherapy {{#subobject:826f82|Regimen=1}}
- 12:58, 30 April 2024 diff hist +44 m Soft tissue sarcoma →References
- 11:33, 30 April 2024 diff hist +20 m Soft tissue sarcoma →Cisplatin monotherapy {{#subobject:6e93fa|Regimen=1}}
- 11:31, 30 April 2024 diff hist +19 m Desmoid tumor current
- 11:29, 30 April 2024 diff hist -7 m Desmoid tumor →Nirogacestat monotherapy {{#subobject:f3agdc|Regimen=1}}
- 11:27, 30 April 2024 diff hist +86 m Breast cancer, triple negative current
- 11:05, 30 April 2024 diff hist +2 m Breast cancer, triple negative →References
- 11:04, 30 April 2024 diff hist +25 m Breast cancer, triple negative →Carboplatin & Gemcitabine (GCb) {{#subobject:d46b34|Regimen=1}}
- 11:03, 30 April 2024 diff hist +2 m Breast cancer, triple negative →References
- 11:02, 30 April 2024 diff hist +2 m Breast cancer, triple negative →References
- 11:01, 30 April 2024 diff hist +44 m Breast cancer, triple negative →References
- 11:00, 30 April 2024 diff hist +46 m Breast cancer, triple negative →FEC-D {{#subobject:0cagj9|Regimen=1}}
- 10:58, 30 April 2024 diff hist +5 m Breast cancer, triple negative →Carboplatin & Docetaxel {{#subobject:82336a|Regimen=1}}
- 10:56, 30 April 2024 diff hist +614 m Breast cancer, triple negative →References
- 23:39, 29 April 2024 diff hist +804 m Breast cancer - null regimens →Placebo current
- 23:33, 29 April 2024 diff hist +166 m Tisotumab vedotin (Tivdak) current
- 23:32, 29 April 2024 diff hist +551 m Cervical cancer →Advanced or metastatic disease, subsequent lines of therapy current
- 23:38, 28 April 2024 diff hist +264 m Lutetium Lu 177 dotatate (Lutathera) →History of changes in FDA indication current
- 21:59, 28 April 2024 diff hist +1,125 Low-grade glioma, pediatric →Temozolomide monotherapy {{#subobject:7b66b|Regimen=1}} current
- 21:54, 28 April 2024 diff hist +1,193 N Tovorafenib (Ojemda) Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tovorafenib NCI Drug Dictionary]: An orally available inhibitor of wild-type..." current
- 21:48, 28 April 2024 diff hist +56 m Drug index →T current
- 12:28, 28 April 2024 diff hist +217 m Upper tract urothelial carcinoma current
- 12:27, 28 April 2024 diff hist +1,402 m Upper tract urothelial carcinoma
- 12:25, 28 April 2024 diff hist +521 m Upper tract urothelial carcinoma - null regimens →References current
- 16:49, 27 April 2024 diff hist +213 m Marginal zone lymphoma current
- 16:46, 27 April 2024 diff hist +3 m Marginal zone lymphoma →References
- 15:02, 27 April 2024 diff hist +258 m Marginal zone lymphoma
- 14:57, 27 April 2024 diff hist +531 m Study Groups →Main table current
- 14:47, 27 April 2024 diff hist -326 m Study Groups →Pediatrics-focused
- 02:08, 25 April 2024 diff hist +65 m Peripheral T-cell lymphoma current
- 02:05, 25 April 2024 diff hist +50 m Peripheral T-cell lymphoma →Mogamulizumab monotherapy {{#subobject:8d8ae3|Regimen=1}}
- 02:04, 25 April 2024 diff hist +182 m Peripheral T-cell lymphoma →Lenalidomide monotherapy {{#subobject:372121|Regimen=1}}
- 02:00, 25 April 2024 diff hist +63 m Peripheral T-cell lymphoma →Forodesine monotherapy {{#subobject:2310b4|Regimen=1}}
- 01:58, 25 April 2024 diff hist +84 m Peripheral T-cell lymphoma →Chidamide monotherapy {{#subobject:5a869f|Regimen=1}}
- 01:56, 25 April 2024 diff hist +65 m Peripheral T-cell lymphoma
- 01:55, 25 April 2024 diff hist +63 m Peripheral T-cell lymphoma →DA-EPOCH {{#subobject:9b4e41|Regimen=1}}
- 01:53, 25 April 2024 diff hist +66 m Peripheral T-cell lymphoma →CHOEP-14 {{#subobject:e84b92|Regimen=1}}
- 01:53, 25 April 2024 diff hist +43 m Peripheral T-cell lymphoma →A-CHOP {{#subobject:75a3d2|Regimen=1}}
- 01:50, 25 April 2024 diff hist -14 m Urothelial carcinoma →References current
- 01:49, 25 April 2024 diff hist +45 m Urothelial carcinoma →References
- 01:48, 25 April 2024 diff hist +45 m Urothelial carcinoma →References
- 01:44, 25 April 2024 diff hist +42 m Urothelial carcinoma →Pembrolizumab monotherapy {{#subobject:7fc2f6|Regimen=1}}
- 01:42, 25 April 2024 diff hist +61 m Urothelial carcinoma →Nivolumab monotherapy {{#subobject:23ugd2|Regimen=1}}
- 01:40, 25 April 2024 diff hist +45 m Bladder cancer →References current
- 01:37, 25 April 2024 diff hist +890 m Multiple myeloma, relapsed-refractory
- 23:08, 24 April 2024 diff hist +1,996 m Chronic lymphocytic leukemia current
- 23:01, 24 April 2024 diff hist +1 m Immune effector cells toxicity management →Consensus recommendations current
- 23:01, 24 April 2024 diff hist +313 m Immune effector cells toxicity management →ASTCT
- 12:52, 24 April 2024 diff hist +1,681 m Nasopharyngeal carcinoma →Locally advanced disease, definitive chemoradiotherapy
- 12:51, 24 April 2024 diff hist +35,495 m Editing test page current
- 11:07, 24 April 2024 diff hist +2,292 m Acute myeloid leukemia →Relapsed or refractory, salvage therapy current
- 11:06, 24 April 2024 diff hist +991 m Acute myeloid leukemia →MEC {{#subobject:48e49b|Regimen=1}}
- 11:03, 24 April 2024 diff hist +4,267 Acute myeloid leukemia →Azacitidine monotherapy {{#subobject:531b70|Regimen=1}}
- 17:34, 23 April 2024 diff hist +13 m Drug index →By Category
- 17:33, 23 April 2024 diff hist +4 m Drug index →Medications by Year of Approval
- 17:33, 23 April 2024 diff hist +42 m Drug index →Medications by Condition
- 17:27, 23 April 2024 diff hist +1,894 m Non-small cell lung cancer, EGFR-mutated →Cisplatin & Pemetrexed {{#subobject:26acke|Regimen=1}} current
- 17:25, 23 April 2024 diff hist +1,184 m Non-small cell lung cancer, EGFR-mutated →Carboplatin & Pemetrexed {{#subobject:60cb1d|Regimen=1}}
- 17:09, 23 April 2024 diff hist +1 m Editing test page →External beam radiotherapy
- 17:09, 23 April 2024 diff hist +3 m Editing test page →External beam radiotherapy
- 17:02, 23 April 2024 diff hist +3 m Nasopharyngeal carcinoma →Radiotherapy
- 17:01, 23 April 2024 diff hist +3 m Nasopharyngeal carcinoma →Regimen variant #1, 30 mg/m2 weekly dosing {{#subobject:c0e2e2|Variant=1}}
- 17:00, 23 April 2024 diff hist +1 m Nasopharyngeal carcinoma →Regimen variant #4, 100 mg/m2 x 2 {{#subobject:b44282|Variant=1}}
- 17:00, 23 April 2024 diff hist 0 m Nasopharyngeal carcinoma →Radiotherapy
- 16:57, 23 April 2024 diff hist +3 m Head and neck cancer →Regimen variant #3, 30 mg/m2 weekly dosing {{#subobject:71731a|Variant=1}}
- 16:37, 23 April 2024 diff hist +1,226 m Non-small cell lung cancer, EGFR-mutated →Carboplatin & Pemetrexed {{#subobject:60cb1d|Regimen=1}}
- 16:24, 23 April 2024 diff hist +2,433 m Colorectal cancer, RAS wild-type →FOLFIRI & Cetuximab {{#subobject:11cf7b|Regimen=1}} current
- 16:15, 23 April 2024 diff hist -1,072 m Colorectal cancer, RAS wild-type
- 12:44, 23 April 2024 diff hist +1,934 m Non-small cell lung cancer, nonsquamous →Carboplatin, Pemetrexed, Atezolizumab {{#subobject:a4hzv7|Regimen=1}} current
- 12:34, 23 April 2024 diff hist +2,209 m Breast cancer, ER-positive →Anastrozole monotherapy {{#subobject:f8140f|Regimen=1}} current
- 11:31, 23 April 2024 diff hist +150 m How I Treat →Transplantation
- 11:30, 23 April 2024 diff hist +172 m How I Treat →Myelodysplastic syndrome (MDS)
- 23:40, 22 April 2024 diff hist +30 m Classical Hodgkin lymphoma, pediatric current
- 23:37, 22 April 2024 diff hist +7 m Small cell lung cancer →Preceding treatment current
- 23:37, 22 April 2024 diff hist +6 m Prostate cancer →Subsequent treatment
- 23:16, 22 April 2024 diff hist -1 m Non-small cell lung cancer →Radiotherapy current
- 23:15, 22 April 2024 diff hist -25 m Non-small cell lung cancer →Subsequent treatment
- 23:14, 22 April 2024 diff hist +13 m Non-small cell lung cancer →Subsequent treatment
- 23:12, 22 April 2024 diff hist +7 m Multiple myeloma - historical →Preceding treatment current
- 23:11, 22 April 2024 diff hist +6 m Multiple myeloma - historical
- 23:10, 22 April 2024 diff hist +7 m Multiple myeloma - historical →Subsequent treatment
- 23:06, 22 April 2024 diff hist +1,516 N Nogapendekin alfa inbakicept (Anktiva) Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nogapendekin-alfa NCI Drug Dictionary]: A fusion protein complex composed of..." current
- 23:00, 22 April 2024 diff hist +74 m Drug index →N
- 13:14, 22 April 2024 diff hist +14 m Breast cancer, ER-positive →Adjuvant therapy, premenopausal
- 13:13, 22 April 2024 diff hist +2,251 m Breast cancer, ER-positive →Goserelin & Tamoxifen {{#subobject:23ef1e|Regimen=1}}
- 13:13, 22 April 2024 diff hist +12 m Breast cancer, ER-positive
- 13:12, 22 April 2024 diff hist +2,256 Breast cancer, ER-positive →Adjuvant therapy, premenopausal
- 13:09, 22 April 2024 diff hist +2,763 m Breast cancer, ER-positive →Anastrozole monotherapy {{#subobject:a052f4|Regimen=1}}
- 13:05, 22 April 2024 diff hist +2 m Breast cancer, ER-positive
- 13:05, 22 April 2024 diff hist +2,760 Breast cancer, ER-positive →Letrozole monotherapy {{#subobject:55e6f9|Regimen=1}}
- 12:52, 22 April 2024 diff hist +630 m Chronic myeloid leukemia →Imatinib monotherapy {{#subobject:917a16|Regimen=1}} current
- 16:46, 21 April 2024 diff hist +6 m Ewing sarcoma current
- 16:42, 21 April 2024 diff hist +7 m Esophageal cancer →Subsequent treatment current
- 16:40, 21 April 2024 diff hist +7 m Diffuse large B-cell lymphoma →Subsequent treatment current
- 16:38, 21 April 2024 diff hist +96 m Classical Hodgkin lymphoma
- 16:34, 21 April 2024 diff hist +7 m Breast cancer →Subsequent treatment
- 16:33, 21 April 2024 diff hist +7 m Breast cancer →Subsequent treatment
- 12:52, 21 April 2024 diff hist +7 m Breast cancer, ER-positive →Preceding treatment
- 12:48, 21 April 2024 diff hist +12 m Breast cancer - historical
- 12:46, 21 April 2024 diff hist -51 m Acute promyelocytic leukemia current
- 12:42, 21 April 2024 diff hist +12 m Acute myeloid leukemia - historical →DAT {{#subobject:fc4f58|Regimen=1}} current
- 20:15, 20 April 2024 diff hist +2,200 m Non-small cell lung cancer →Carboplatin & Docetaxel {{#subobject:bdce59|Regimen=1}}
- 20:06, 20 April 2024 diff hist +1,560 m Breast cancer - historical →STAMP-I {{#subobject:c08ab4|Regimen=1}}
- 20:05, 20 April 2024 diff hist -1,561 m Breast cancer - historical →VAP {{#subobject:4b99b8|Regimen=1}}
- 20:04, 20 April 2024 diff hist +513 m Breast cancer - historical →CTCb, then auto HSCT {{#subobject:02f569|Regimen=1}}
- 19:55, 20 April 2024 diff hist +2,042 m Breast cancer - historical →CHUT, then auto HSCT {{#subobject:e9e363|Regimen=1}}
- 19:55, 20 April 2024 diff hist -2,042 m Breast cancer - historical →CTCb, then auto HSCT {{#subobject:02f569|Regimen=1}}
- 19:54, 20 April 2024 diff hist +2,013 m Breast cancer - historical →CHUT, then auto HSCT {{#subobject:e9e363|Regimen=1}}
- 19:53, 20 April 2024 diff hist +1,366 m Breast cancer - historical →Mitoxantrone & Vinorelbine (MV) {{#subobject:eb48ba|Regimen=1}}
- 19:50, 20 April 2024 diff hist -2,555 m Breast cancer - historical →STAMP-I {{#subobject:c08ab4|Regimen=1}}
- 19:47, 20 April 2024 diff hist +61 m Breast cancer - historical →Metastatic disease, first-line therapy
- 18:32, 20 April 2024 diff hist +118 m Acute myeloid leukemia →Upfront induction therapy, standard and older "fit" patients
- 12:56, 20 April 2024 diff hist +44 m Esophageal cancer →References
- 12:54, 20 April 2024 diff hist +68 m Esophageal cancer
- 00:40, 20 April 2024 diff hist -140 m Cutaneous squamous cell carcinoma current
- 00:39, 20 April 2024 diff hist +69 m Classical Hodgkin lymphoma
- 00:37, 20 April 2024 diff hist +845 m Classical Hodgkin lymphoma
- 00:37, 20 April 2024 diff hist -7 m Autologous HSCT →References current
- 00:36, 20 April 2024 diff hist +63 m Autologous HSCT →Regimen {{#subobject:81ff2e|Variant=1}}
- 00:22, 20 April 2024 diff hist +35 m Head and neck cancer
- 00:20, 20 April 2024 diff hist +186 m Colorectal cancer current
- 00:17, 20 April 2024 diff hist +251 m Non-small cell lung cancer
- 00:11, 20 April 2024 diff hist +69 m Malignant solid neoplasm, ERBB2-mutated →Trastuzumab emtansine monotherapy {{#subobject:0a0a41|Regimen=1}} current
- 00:10, 20 April 2024 diff hist +67 m Malignant solid neoplasm, ERBB2-mutated →Neratinib monotherapy {{#subobject:3c1a9c|Regimen=1}}
- 00:09, 20 April 2024 diff hist +1,507 Malignant solid neoplasm, ERBB2-mutated →Trastuzumab emtansine monotherapy {{#subobject:0a0a41|Regimen=1}}
- 00:03, 20 April 2024 diff hist +453 m Trastuzumab deruxtecan (Enhertu) current
- 23:55, 19 April 2024 diff hist 0 m Urothelial carcinoma
- 23:50, 19 April 2024 diff hist +3 m Melanoma →Regimen variant #1, 2 mg/kg q3wk {{#subobject:25a9fe|Variant=1}} current
- 23:49, 19 April 2024 diff hist +3 m Melanoma →Regimen variant #2, indefinite {{#subobject:722e51|Variant=1}}
- 16:37, 19 April 2024 diff hist +230 m Opioid Conversion Table current
- 16:22, 19 April 2024 diff hist +745 m B-cell acute lymphoblastic leukemia, pediatric →References current
- 12:34, 19 April 2024 diff hist 0 m Mantle cell lymphoma →Lenalidomide monotherapy {{#subobject:b5de78|Regimen=1}} current
- 12:32, 19 April 2024 diff hist +594 m Head and neck cancer →Methotrexate monotherapy {{#subobject:0e90b2|Regimen=1}}
- 12:30, 19 April 2024 diff hist +280 m Glioblastoma →Carmustine & RT {{#subobject:ee9fbd|Regimen=1}} current
- 12:25, 19 April 2024 diff hist +293 m Head and neck cancer →Cetuximab monotherapy {{#subobject:4b973b|Regimen=1}}
- 12:24, 19 April 2024 diff hist +933 m Head and neck cancer →Docetaxel monotherapy {{#subobject:623c3f|Regimen=1}}
- 12:15, 19 April 2024 diff hist -36 m B-cell acute lymphoblastic leukemia, Ph-positive →Dasatinib, Vincristine, Prednisone {{#subobject:71a41c|Regimen=1}} current
- 12:11, 19 April 2024 diff hist +3 m Acute myeloid leukemia, FLT3-positive →Regimen {{#subobject:bd7f87|Variant=1}} current
- 12:11, 19 April 2024 diff hist +3 m Acute myeloid leukemia, FLT3-positive →FLAG-Ida {{#subobject:d8c75b|Regimen=1}}
- 12:10, 19 April 2024 diff hist +3 m Acute myeloid leukemia, FLT3-positive →Regimen {{#subobject:c9nqa0|Variant=1}}
- 11:17, 19 April 2024 diff hist +337 m Chronic lymphocytic leukemia →Ofatumumab monotherapy {{#subobject:75bd7e|Regimen=1}}
- 11:12, 19 April 2024 diff hist -4 m Breast cancer, triple negative
- 11:11, 19 April 2024 diff hist -1 m Breast cancer, triple negative →Paclitaxel & Pembrolizumab {{#subobject:2g8gua|Regimen=1}}
- 11:07, 19 April 2024 diff hist +29 m Breast cancer, BRCA-mutated →Regimen variant #2, 300 mg twice per day {{#subobject:3b0774|Variant=1}} current
- 11:00, 19 April 2024 diff hist +8 m Colorectal cancer, MSI-H or dMMR →Regimen {{#subobject:3af038|Variant=1}} current
- 11:00, 19 April 2024 diff hist +2 m Colorectal cancer, MSI-H or dMMR →Regimen {{#subobject:3af038|Variant=1}}
- 10:59, 19 April 2024 diff hist -65 m Colorectal cancer, MSI-H or dMMR →Pembrolizumab monotherapy {{#subobject:5aa59d|Regimen=1}}
- 00:36, 19 April 2024 diff hist -1 m Esophageal squamous cell carcinoma →Nivolumab monotherapy {{#subobject:10ee99|Regimen=1}} current
- 00:35, 19 April 2024 diff hist -1 m Esophageal squamous cell carcinoma →Regimen {{#subobject:d1dde0|Variant=1}}
- 00:35, 19 April 2024 diff hist +29 m Esophageal squamous cell carcinoma →Camrelizumab monotherapy {{#subobject:c701c3|Regimen=1}}
- 00:29, 19 April 2024 diff hist -39 m Non-small cell lung cancer, nonsquamous →Regimen variant #2, 5/500 x 4, then maintenance pem x 2y {{#subobject:1mwjm3|Variant=1}}
- 00:19, 19 April 2024 diff hist +1,816 Ovarian cancer, HRD-positive →Paclitaxel monotherapy {{#subobject:f47paa|Regimen=1}} current
- 00:17, 19 April 2024 diff hist +1,791 Ovarian cancer, HRD-positive →Paclitaxel monotherapy {{#subobject:f47paa|Regimen=1}}
- 00:16, 19 April 2024 diff hist +1,794 Ovarian cancer, HRD-positive →Olaparib monotherapy {{#subobject:f47yha|Regimen=1}}
- 00:14, 19 April 2024 diff hist +686 m Ovarian cancer, HRD-positive
- 00:14, 19 April 2024 diff hist -686 m Ovarian cancer, HRD-positive
- 00:13, 19 April 2024 diff hist +1,813 Ovarian cancer, HRD-positive →Olaparib monotherapy {{#subobject:f47yha|Regimen=1}}
- 23:47, 18 April 2024 diff hist -2 m Gastric cancer, HER2-positive →Regimen {{#subobject:577cd6|Variant=1}} current
- 23:44, 18 April 2024 diff hist +3 m Peripheral T-cell lymphoma →References
- 23:44, 18 April 2024 diff hist +19 m Peripheral T-cell lymphoma →Gemcitabine monotherapy {{#subobject:7dbc1c|Regimen=1}}
- 23:43, 18 April 2024 diff hist +2 m Peripheral T-cell lymphoma - historical →References current
- 23:39, 18 April 2024 diff hist +807 m Clear cell renal cell carcinoma current
- 23:36, 18 April 2024 diff hist +730 m Clear cell renal cell carcinoma - null regimens →Placebo current
- 20:40, 18 April 2024 diff hist +4 m Non-small cell lung cancer, ALK-positive →Regimen {{#subobject:9cef11|Variant=1}} current
- 20:39, 18 April 2024 diff hist +255 m Alectinib (Alecensa) →History of changes in FDA indication current
- 17:14, 16 April 2024 diff hist -1 m Drug shortages →Links current
- 19:37, 15 April 2024 diff hist +38 m Multiple myeloma - historical →Melphalan monotherapy, then auto HSCT, then Melphalan & TBI, then auto HSCT {{#subobject:9ac748|Regimen=1}}
- 19:31, 15 April 2024 diff hist 0 m Multiple myeloma - historical →Melphalan monotherapy, then auto HSCT, then Melphalan & Busulfan, then auto HSCT {{#subobject:71ae0c|Regimen=1}}
- 19:30, 15 April 2024 diff hist +308 m Multiple myeloma - historical →MEL200, then auto HSCT, then MEL220 & Dexamethasone, then auto HSCT {{#subobject:9f3119|Regimen=1}}
- 19:25, 15 April 2024 diff hist +330 m Multiple myeloma - historical →Melphalan monotherapy, then auto HSCT, then Melphalan & Busulfan, then auto HSCT {{#subobject:71ae0c|Regimen=1}}
- 19:20, 15 April 2024 diff hist -1 m Multiple myeloma, consolidation and maintenance →Thalidomide & Prednisolone (TP) {{#subobject:1agdc9|Regimen=1}} current
- 18:42, 15 April 2024 diff hist +255 m Follicular lymphoma - historical →131Iodine-Tositumomab monotherapy {{#subobject:f69726|Regimen=1}}
- 17:48, 15 April 2024 diff hist -1 m Breast cancer - historical →CEF/CMF {{#subobject:682333|Regimen=1}}
- 17:04, 15 April 2024 diff hist +16 m CNS lymphoma →Nordic Regimen, younger patients {{#subobject:e571ce|Regimen=1}} current
- 17:02, 15 April 2024 diff hist +2 m Rhabdomyosarcoma, pediatric
- 17:35, 14 April 2024 diff hist -39 m Urothelial carcinoma - null regimens →Preceding treatment current
- 17:35, 14 April 2024 diff hist -13 m Urothelial carcinoma →Preceding treatment
- 17:34, 14 April 2024 diff hist +12 m Urothelial carcinoma - null regimens →Preceding treatment
- 17:33, 14 April 2024 diff hist +9 m Testicular cancer →Regimen variant #5, 45/500/100 (modified BEP) {{#subobject:fd61db|Variant=1}} current